Protocol Ledger

NCT05185843 · Phase III · ACTIVE NOT RECRUITING

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Interventional Phase III clinical trial protocol NCT05185843 sponsored by Ionis Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-25 Enrollment: 24 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05185843
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05185843
Protocol FieldVerified Registry Value
NCT IdentifierNCT05185843
Consolidated Lead SponsorIonis Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment24 participants (ACTUAL)
Registered Start Date2022-02-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05185843
Hospital Research SiteLocationSite Profile
University of Michigan Rogel Cancer CenterAnn Arbor, MIOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI